POLB.F Stock Overview
Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.17 |
| 52 Week High | UK£0.23 |
| 52 Week Low | UK£0.11 |
| Beta | 2.19 |
| 11 Month Change | 0% |
| 3 Month Change | 25.90% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| POLB.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -2.9% |
| 1Y | n/a | 19.0% | 17.2% |
Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.
Price Volatility
| POLB.F volatility | |
|---|---|
| POLB.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: POLB.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Poolbeg Pharma PLC Fundamentals Summary
| POLB.F fundamental statistics | |
|---|---|
| Market cap | US$81.29m |
| Earnings (TTM) | -US$5.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.1x
P/E RatioIs POLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLB.F income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.93m |
| Earnings | -UK£3.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0079 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did POLB.F perform over the long term?
See historical performance and comparison